Compare FDMT & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDMT | TALK |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.8M | 442.1M |
| IPO Year | 2020 | N/A |
| Metric | FDMT | TALK |
|---|---|---|
| Price | $10.99 | $3.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $30.33 | $4.83 |
| AVG Volume (30 Days) | 767.4K | ★ 1.0M |
| Earning Date | 11-10-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $120,000.00 | ★ $214,593,000.00 |
| Revenue This Year | $21,181.08 | $23.86 |
| Revenue Next Year | $162.43 | $22.22 |
| P/E Ratio | ★ N/A | $138.93 |
| Revenue Growth | ★ 605.88 | 18.37 |
| 52 Week Low | $2.24 | $2.22 |
| 52 Week High | $12.34 | $4.36 |
| Indicator | FDMT | TALK |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 64.01 |
| Support Level | $10.30 | $3.07 |
| Resistance Level | $11.50 | $3.21 |
| Average True Range (ATR) | 0.70 | 0.13 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 56.85 | 93.88 |
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.